This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
Real validated CD1A Western blot protocols, expected-band and isoform facts, troubleshooting for weak or shifted signal, and recommended anti-CD1A WB antibodies. Everything you need to plan the experiment before you commit precious samples.
Expected bands, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
| Expected band | ~37.1 kDa | |
| Observed band | ~37 kDa | |
| Gel | 5–20% (catalog PA1875) | |
| Positive control | Skin (IHC candidate; verify WB) +2 more | |
| Negative control | Adipose tissue (IHC candidate; verify WB) |
| PTM | Glycosylated + Cleaved | |
| Caveat | Glycosylation-state controls | |
| Gene-set association | MSigDB C7 membership | |
| Isoform | 1 isoform(s) |
The PA1875 protocol combines labelled catalog values with standard starting conditions. Published comparisons retain their own sample, reagent and detection scope.
| Sample / lysate | human Jurkat (catalog PA1875) |
| Gel % | 5–20% (catalog PA1875) |
| Load | 30 ug; reducing conditions (catalog PA1875) |
| Transfer | a nitrocellulose membrane at 150 mA for 50-90 minutes (catalog PA1875) |
| Membrane | nitrocellulose membrane (catalog PA1875) |
| Blocking | 5% non-fat milk/TBS for 1.5 hour at RT (catalog PA1875) |
| Primary antibody | PA1875 · 0.5 μg/mL (catalog PA1875) |
| Primary incubation | overnight at 4°C (catalog PA1875) |
| Secondary antibody | goat anti-rabbit IgG-HRP, 1:5000 (catalog PA1875) |
| Secondary incubation | 1.5 hour at RT (catalog PA1875) |
| Wash | TBS-0.1%Tween 3 times with 5 minutes each (catalog PA1875) |
| Detection | ECL (catalog PA1875) |
CD1a is predicted at 37.1 kDa and observed at ~37 kDa; the cause of their small apparent difference is not established.
| Band at ~37 kDa | Empirical CD1a band near its 37.1 kDa predicted precursor mass |
| Band below ~37 kDa | Could reflect signal peptide removal; identity requires confirmation |
| Band above ~37 kDa | Could reflect N-linked glycosylation; a visible shift is unproven |
| Broad smear near the expected region | Could reflect variable N-linked glycosylation; heterogeneity is unproven |
| Predicted precursor mass | 37.1 kDa predicted; the empirical CD1a band is ~37 kDa |
| N-linked glycosylation site at Asn37 | Could affect migration if occupied; shift magnitude is unknown |
| N-linked glycosylation site at Asn60 | Could affect migration if occupied; shift magnitude is unknown |
| N-linked glycosylation site at Asn74 | Could affect migration if occupied; shift magnitude is unknown |
| N-linked glycosylation site at Asn145 | Could affect migration if occupied; shift magnitude is unknown |
| Signal peptide at residues 1–16 | Cleavage yields a smaller mature chain, without a demonstrated resolvable shift |
| Situation | Likely cause | Next action |
|---|---|---|
| No band in lysate | Membrane-associated CD1a may be poorly recovered | Check membrane extraction and run a CD1a-positive control |
| Band higher than expected | N-linked glycosylation could affect migration | Compare paired samples with and without N-glycan removal |
| Band lower than expected | Signal peptide cleavage could reduce chain size | Verify identity with a second antibody and a positive control |
| Broad smear instead of sharp band | Variable N-linked glycosylation is possible | Compare paired samples with and without N-glycan removal |
| Multiple bands | Glycosylation or signal peptide processing could contribute | Compare glycan removal results and confirm bands with a second antibody |
| Weak or no signal | Membrane-associated CD1a may be underrepresented in the preparation | Enrich membrane protein and check a CD1a-positive control |
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Skin | fibrohistiocytic cells | High | Protein (IHC) | HPA → |
| Thymus | cortical cells | High | Protein (IHC) | HPA → |
| Tonsil | non-germinal center cells | Medium | Protein (IHC) | HPA → |
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | adipocytes | Not detected | Protein (IHC) | HPA → |
| Adrenal gland | glandular cells | Not detected | Protein (IHC) | HPA → |
| Appendix | glandular cells | Not detected | Protein (IHC) | HPA → |
| Bone marrow | hematopoietic cells | Not detected | Protein (IHC) | HPA → |
| Breast | adipocytes | Not detected | Protein (IHC) | HPA → |
Deeper troubleshooting and optimisation questions for CD1A, answered from its protein features.
Catalog antibodies with Western blot application and product-specific WB images. Evaluate suitability with the reported sample, controls and experimental conditions.
Two the supplier anti-CD1a antibodies are listed for human Western blotting. PA1875 has an image showing an approximately 37 kDa band in Jurkat whole-cell lysate; M00375-2 has an image from human fetal thymus lysate. These images document specific tested samples, not broader validation.
Which to pick: Choose PA1875 for a documented Jurkat lysate protocol with a reported 37 kDa band and 0.5 μg/mL primary antibody. Choose M00375-2 if the fetal thymus example better matches your sample; its supplied caption gives no antibody concentration or band size. Both list human reactivity.